Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Evaluating the Kinetics of Absolute Lymphocyte Counts Following Bispecific T-Cell Engager Therapy to Predict Clinical Outcomes in Relapsed/Refractory Multiple Myeloma

Emmanuel Bugarin-Estrada, Jorge Monge, Roger Pearse, Ruben Niesvizky, Mateo Mejia Saldarriaga

Blood (2024) 144 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2024-209148

Published: 2024

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Blood (2024) 144 (Supplement 1): 7039.

https://doi.org/10.1182/blood-2024-210376

Published: 2024

Journal Articles

Disease Course and Risk Model Validation of Asymptomatic Waldenström Macroglobulinemia Patients - a Single Center Experience

Theresia Akhlaghi, Jose Fernandez-Rengifo, Mateo Mejia Saldarriaga, Sarah C. Rutherford, Cara Rosenbaum, Jorge Monge, Peter Martin, John N. Allan, Richard R. Furman, Ruben Niesvizky, Mark Bustoros

Blood (2024) 144 (Supplement 1): 6350.

https://doi.org/10.1182/blood-2024-210059

Published: 2024

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Blood (2024) 144 (Supplement 1): 7012.

https://doi.org/10.1182/blood-2024-200679

Published: 2024

Journal Articles

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Caitlin Unkenholz, Mateo Mejia Saldarriaga, Esther Ortega, Jorge Monge, Christian A Gordillo, Juan Esteban Velez-Hernandez, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2024) 144 (Supplement 1): 1936.

https://doi.org/10.1182/blood-2024-210365

Published: 2024

Journal Articles

Prognostic Factors for Survival in Multiple Myeloma Patients That Receive Bispecific Antibodies: Does Relative Dose Intensity Matters?

Henry Becerra, Emmanuel Bugarin-Estrada, Ruben Niesvizky, Roger Pearse, Jorge Monge, Mateo Mejia Saldarriaga

Blood (2024) 144 (Supplement 1): 1930.

https://doi.org/10.1182/blood-2024-211033

Published: 2024

Journal Articles

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Nizar J Bahlis, Suzanne Trudel, Christopher Maisel, Lisa X. Lee, Jorge Monge, Claudia Paba Prada, Sarah M. Larson, Guenther Koehne, Yogesh Jethava, Wei Dong Ma, Cristina De Nicolo, Isabel Perez-Cruz

Blood (2023) 142 (Supplement 1): 6737.

https://doi.org/10.1182/blood-2023-189700

Published: 2023

Journal Articles

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Blood (2023) 142 (Supplement 1): 545.

https://doi.org/10.1182/blood-2023-174875

Published: 2023

Journal Articles

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Beth Gordon, Lindsay Fogel, Gaurav Varma, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Xiaoyi Chen, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S. Siegel, Gareth J. Morgan, Ruben Niesvizky, Noa Biran, Faith E. Davies

Blood (2023) 142 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2023-181304

Published: 2023

Journal Articles

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Mateo Mejia Saldarriaga, Caitlin Unkenholz, Joshua A Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, Markus Mapara, Giorgio Inghirami, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2023) 142 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2023-187832

Published: 2023

Journal Articles

Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study

Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Radhakrishnan, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Meera Mohan

Blood (2023) 142 (Supplement 1): 358.

https://doi.org/10.1182/blood-2023-182695

Published: 2023

Journal Articles

Clinical and Genomics Characteristics of Multiple Myeloma with Extramedullary Disease in the Mmrf Registry

Mateo Mejia Saldarriaga, David S Jayabalan, Aubrie Sowa, Jorge Monge, Cara A. Rosenbaum, Roger Pearse, Ruben Niesvizky, Sanjay Patel, Mark Bustoros

Blood (2022) 140 (Supplement 1): 4238–4239.

https://doi.org/10.1182/blood-2022-157191

Published: 2022

Journal Articles

Young Adults with Multiple Myeloma Have Distinct Clinical and Molecular Characteristics Compared to Older Patients

Mateo Mejia Saldarriaga, Aubrie Sowa, David S Jayabalan, Cara A. Rosenbaum, Roger Pearse, Jorge Monge, Ruben Niesvizky, Mark Bustoros

Blood (2022) 140 (Supplement 1): 9951–9952.

https://doi.org/10.1182/blood-2022-170413

Published: 2022

Journal Articles

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Blood (2021) 138 (Supplement 1): 2751.

https://doi.org/10.1182/blood-2021-150998

Published: 2021

Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2757.

https://doi.org/10.1182/blood-2021-145903

Published: 2021

Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2021-148759

Published: 2021

Journal Articles

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Blood (2021) 138 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2021-150232

Published: 2021

Journal Articles

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Jorge Monge, MD, Jorge Contreras, MD, Sarah Elsoukkary, MD, Jin Guo, MD, Art Perry, PA, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Morton Coleman, MD, Adriana C. Rossi, MDMSc, Rebecca Harris, MD, Markus Plate, MD, Joerg-Patrick Stuebgen, MB, ChB, MD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 4876.

https://doi.org/10.1182/blood-2019-122134

Published: 2019

Journal Articles

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Eloisi Caldas Lopes, PhD, Tai Wang, PhD, David S Jayabalan, MSc, Tony Taldone, PhD, Jorge Monge, MD, Jorge Contreras, MD, Yip Winnie, Vicenta Trujillo, PhD, Panchal Palak, Nicholas Lombardi, Sharma Sahil, PhD, Digwal Chander, PhD, Morton Coleman, MD, Gabriela Chiosis, PhD, Ruben Niesvizky, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 4399.

https://doi.org/10.1182/blood-2019-125267

Published: 2019

NARROW

Evaluating the Kinetics of Absolute Lymphocyte Counts Following Bispecific T-Cell Engager Therapy to Predict Clinical Outcomes in Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Disease Course and Risk Model Validation of Asymptomatic Waldenström Macroglobulinemia Patients - a Single Center Experience

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Prognostic Factors for Survival in Multiple Myeloma Patients That Receive Bispecific Antibodies: Does Relative Dose Intensity Matters?

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study

Clinical and Genomics Characteristics of Multiple Myeloma with Extramedullary Disease in the Mmrf Registry

Young Adults with Multiple Myeloma Have Distinct Clinical and Molecular Characteristics Compared to Older Patients

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only